rethinkTHC Search
Menu
Study breakdown

The body's own cannabinoids killed glioblastoma cells by disrupting their mitochondria, through a receptor pathway beyond the usual cannabinoid targets

ObservationalPreliminary evidence
The takeaway

Anandamide and oleamide showed anti-proliferative effects in glioblastoma cells by disrupting mitochondrial function through PPAR-gamma receptors, while sparing normal brain cells, suggesting a non-classical cannabinoid mechanism against brain cancer.

Neuro-oncology researchers, scientists studying endocannabinoid biology, and those interested in non-classical cannabinoid receptor pathways.

Endocannabinoids selectively killed cancer cells via mitochondrial disruption

What the researchers found

Anandamide (AEA) and oleamide (ODA) reduced glioblastoma cell viability and increased lipid peroxidation compared to normal astrocytes. Both reduced mitochondrial membrane potential and impaired Complex I activity in C6 cells. The PPAR-gamma antagonist GW9662 showed differential effects, indicating PPAR-gamma involvement varies by cell type.

Why it matters

Unlike the CBD kidney cancer study (RTHC-08638), these endocannabinoids showed selectivity for cancer cells over normal brain cells, and they work through a non-classical receptor pathway (PPAR-gamma) that could be more therapeutically accessible.

The numbers in context

Two glioblastoma lines (C6, RG2) vs. primary astrocyte controls. AEA and ODA reduced viability and increased lipid peroxidation in cancer but not normal cells. Mitochondrial membrane potential decreased in C6 but not RG2. Complex I inhibited in C6 cells.

How the study worked

In vitro study using two glioblastoma cell lines (C6 and RG2) and primary astrocyte cultures as non-tumor controls. Cell viability, lipid peroxidation, mitochondrial membrane potential, and Complex I activity were measured after AEA and ODA treatment, with and without the PPAR-gamma antagonist GW9662.

What this study cannot tell us

In vitro study only. Two glioblastoma cell lines showed different responses, suggesting results are cell-type dependent. Endocannabinoid concentrations used may not reflect physiological brain levels. Primary astrocytes may not perfectly represent all normal brain cell types.

How to read the evidence

Preliminary: in vitro study with two cell lines showing differential responses and mechanistic complexity.

When this study was published

Published 2026.

The bigger picture

Glioblastoma remains one of the most lethal cancers. The finding that endocannabinoids selectively target cancer cell mitochondria through PPAR-gamma, rather than classical CB1/CB2 receptors, opens a distinct therapeutic avenue from traditional cannabinoid approaches.

Questions still open

  • Why do C6 and RG2 glioblastoma cells respond differently to mitochondrial disruption? Could PPAR-gamma agonists be combined with standard glioblastoma treatment? Do these endocannabinoid-mitochondrial effects occur in vivo?

Common questions

Can the body's own cannabinoids fight brain cancer?
In this lab study, anandamide and oleamide selectively killed glioblastoma cells while sparing normal brain cells, by disrupting cancer cell mitochondria through PPAR-gamma receptors.
How is this different from CBD cancer research?
Unlike CBD, which often lacks tumor selectivity in lab studies, these endocannabinoids showed preferential anti-cancer effects on glioblastoma cells compared to normal astrocytes, working through a non-classical receptor pathway.

Read the original research

The Anti-proliferative Effects of Anandamide and Oleamide in Glioblastoma Cell Lines Recruit Mitochondrial and PPAR-γ Receptor Modulation.

Neurochemical research, 51(1), 43

Citation

Torres-Román, Ana Laura; Ortega-Gómez, Alette; Reyes-Soto, Carolina Y; Aparicio-Trejo, Omar Emiliano; Cuevas-López, Belén; García-Arroyo, Fernando E; Ruíz-García, Erika; Matus-Santos, Juan A; Ferrer, Beatriz; Aschner, Michael; Jardón, Gustavo; López-Goerne, Tessy; Molina-Hernández, Anayansi; Tenorio-Monterrubio, Juan Carlos; Santamaría, Abel. (2026). The Anti-proliferative Effects of Anandamide and Oleamide in Glioblastoma Cell Lines Recruit Mitochondrial and PPAR-γ Receptor Modulation.. Neurochemical research, 51(1), 43. https://doi.org/10.1007/s11064-025-04654-x

Explore the wider topic